BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng M, Luan S, Gao S, Cheng L, Hao B, Li J, Chen Y, Hou X, Chen L, Li H. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. Oncotarget 2017;8:39143-53. [PMID: 28388576 DOI: 10.18632/oncotarget.16609] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
2 Nassar H, Abu-dahab R, Taha M. Inhibition of protein kinases by proton pump inhibitors: computational screening and in vitro evaluation. Med Chem Res 2021;30:2266-76. [DOI: 10.1007/s00044-021-02812-8] [Reference Citation Analysis]
3 Spugnini EP, Fais S. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opin Ther Pat 2020;30:15-25. [PMID: 31847622 DOI: 10.1080/13543776.2020.1704733] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
4 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Hu QF, Gao TT, Shi YJ, Lei Q, Liu ZH, Feng Q, Chen ZJ, Yu LT. Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK. Eur J Med Chem 2019;162:407-22. [PMID: 30453248 DOI: 10.1016/j.ejmech.2018.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33:614-624. [PMID: 30071147 DOI: 10.1002/ncp.10181] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
7 Zhang C, Tan X, Feng J, Ding N, Li Y, Jin Z, Meng Q, Liu X, Hu C. Design, Synthesis and Biological Evaluation of a New Series of 1-Aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea Derivatives as Antiproliferative Agents. Molecules 2019;24:E2108. [PMID: 31167363 DOI: 10.3390/molecules24112108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Pirovano G, Roberts S, Brand C, Donabedian PL, Mason C, de Souza PD, Higgins GS, Reiner T. [18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model. Mol Imaging Biol 2019;21:705-12. [PMID: 30357568 DOI: 10.1007/s11307-018-1288-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zhang L, Wang F, Yi H, Ermakova SP, Malyarenko OS, Mo J, Huang Y, Duan Q, Xiao J, Zhu F. The role of T-LAK cell-originated protein kinase in targeted cancer therapy. Mol Cell Biochem 2022. [PMID: 35037144 DOI: 10.1007/s11010-021-04329-5] [Reference Citation Analysis]
10 Huang H, Lee MH, Liu K, Dong Z, Ryoo Z, Kim MO. PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential. Cancers (Basel) 2021;13:2232. [PMID: 34066486 DOI: 10.3390/cancers13092232] [Reference Citation Analysis]
11 Pirovano G, Roberts S, Reiner T. TOPKi-NBD: a fluorescent small molecule for tumor imaging. Eur J Nucl Med Mol Imaging 2020;47:1003-10. [PMID: 31734783 DOI: 10.1007/s00259-019-04608-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Turanli B, Altay O, Borén J, Turkez H, Nielsen J, Uhlen M, Arga KY, Mardinoglu A. Systems biology based drug repositioning for development of cancer therapy. Semin Cancer Biol 2021;68:47-58. [PMID: 31568815 DOI: 10.1016/j.semcancer.2019.09.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
13 Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, Sausville EL, Lukow DA, Liu L, Chait AR, Galluzzo ZC, Tucker C, Sheltzer JM. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 2019;11:eaaw8412. [PMID: 31511426 DOI: 10.1126/scitranslmed.aaw8412] [Cited by in Crossref: 173] [Cited by in F6Publishing: 142] [Article Influence: 86.5] [Reference Citation Analysis]